title: In vivo antibody response and in vitro CTL activation induced by selected measles vaccine candidates, prepared with purified Quil A components.
abstract: Semipurified Quil A and purified Quil A were used to prepare well-characterized subunit vaccine candidates against measles. Variation in the relative amounts of the measles virus (MV) fusion (F) protein, Quil A-components and lipids did not influence induction of antibody responses in mice, but had a pronounced effect on the capacity to induce cytotoxic T cell (CTL) activity of a CD8(+) MV F-protein specific human T cell clone in vitro. A characteristic MV iscom preparation based on the combined use of HPLC-purified Quil A-components QA-3 and QA-22 (QA-3/22) efficiently induced CTL activity in vitro. Comparable results were obtained by mixing beta-propiolactone inactivated MV with iscom-matrix QA-3/22 or free QA-22. On the basis of the data presented it was concluded that these three preparations are interesting MV vaccine candidates for further evaluation in pre-clinical experiments in a primate model.
authors.affiliation: Laboratory for Vaccine Research, Institute of Public Health and the Environment, 3720 BA, Bilthoven, The Netherlands.
authors.forename: K J
authors.initials: KJ
authors.lastname: Stittelaar
authors.forename: J
authors.initials: J
authors.lastname: Boes
authors.forename: G F
authors.initials: GF
authors.lastname: Kersten
authors.forename: A
authors.initials: A
authors.lastname: Spiekstra
authors.forename: P G
authors.initials: PG
authors.lastname: Mulder
authors.forename: P
authors.initials: P
authors.lastname: de Vries
authors.forename: P J
authors.initials: PJ
authors.lastname: Roholl
authors.forename: K
authors.initials: K
authors.lastname: Dalsgaard
authors.forename: G
authors.initials: G
authors.lastname: van den Dobbelsteen
authors.forename: L
authors.initials: L
authors.lastname: van Alphen
authors.forename: A D
authors.initials: AD
authors.lastname: Osterhaus
mesh_terms: D000276:Adjuvants, Immunologic / Q000737:chemistry* / Q000302:isolation & purification; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis*; D002478:Cells, Cultured; D002522:Chlorocebus aethiops; D002851:Chromatography, High Pressure Liquid; D003602:Cytotoxicity, Immunologic; D006389:Hemagglutinins, Viral / Q000276:immunology*; D006801:Humans; D016882:ISCOMs / Q000737:chemistry / Q000276:immunology*; D008213:Lymphocyte Activation; D008458:Measles Vaccine / Q000737:chemistry / Q000276:immunology*; D008459:Measles virus / Q000187:drug effects / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008854:Microscopy, Electron; D011420:Propiolactone / Q000494:pharmacology; D062605:Quillaja Saponins; D012503:Saponins / Q000737:chemistry / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000276:immunology; D014709:Vero Cells; D014760:Viral Fusion Proteins / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D006389:Hemagglutinins, Viral; D016882:ISCOMs; D008458:Measles Vaccine; D062605:Quillaja Saponins; D012503:Saponins; D014613:Vaccines, Attenuated; D014760:Viral Fusion Proteins; C032397:hemagglutinin protein G, measles virus; C046386:Quil A; D011420:Propiolactone